‘EXTREMELY IMPRESSIVE': MELANOMA JAB TRIAL RESULTS EXCITE DOCTORS

Summary from the TLDR newsletter

A mRNA cancer vaccine for melanoma halves the risk of patients dying or the disease returning after three years. The vaccine is custom-built for each patient and specific to each patient's tumor. The average risk of recurrence for the type of advanced cancer the study focused on is 50%, but the vaccine brought the risk of recurrence down to 25%. The data from the study suggests that levels of cancer relapse did not increase in people with high-risk, advanced-stage melanoma.